rabeximod   Click here for help

GtoPdb Ligand ID: 9856

Synonyms: Rob-803 | Rob803
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Rabeximod is an orally active immunomodulator. It has potent anti-rheumatic effects in animal models and is being evaluated as a potential drug for rheumatoid arthritis patients. The structure was originally claimed in patent WO2005123741A1 (Compound E) for anti-inflammatory potential [1], and later for antiviral potential in patent WO2014140321A1 (example 2). The molecular mechanism of action of this compound vis its anti-inflammatory activity remains unclear.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 63.05
Molecular weight 409.17
XLogP 4.11
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CN(CCNC(=O)Cn1c2ccc(cc2c2c1nc1cc(C)c(cc1n2)C)Cl)C
Isomeric SMILES CN(CCNC(=O)Cn1c2ccc(cc2c2c1nc1cc(C)c(cc1n2)C)Cl)C
InChI InChI=1S/C22H24ClN5O/c1-13-9-17-18(10-14(13)2)26-22-21(25-17)16-11-15(23)5-6-19(16)28(22)12-20(29)24-7-8-27(3)4/h5-6,9-11H,7-8,12H2,1-4H3,(H,24,29)
Immunopharmacology Comments
Rabeximod (Rob 803) exhibits anti-rheumatic efficacy in in vitro arthritis models [3]. It appears to act early in monocyte differentiation, to inhibit monocyte differentiation to pro-inflammatory professional antigen presenting cells, as well attenuating the immunostimulatory capacity of these cells [2]. Its molecular target has yet to be defined.
Immunopharmacology Disease
Disease X-Refs Comment References
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Phase 2 evaluation as an adjunct to methotrexate therapy in RA has been completed- see NCT00525213